Structure Encountered
Akari Therapeutics
Builds antibody-drug conjugates with a spliceosome-modulating payload for solid tumors
Akari's TROP2 spliceosome ADC AKTX-101 showed synergy with adagrasib in KRAS-mutated pancreatic cancer models.
SIGNAL·Preclinical combination data, ASCO abstract accepted·Synergy reported in KRAS G12C and G12D pancreatic cancer cell lines, no quantitative metrics disclosed·SCORE 60·02 JUN 2026 · 11:54 UTC
● CAPTURE — IMAGE INCOMINGFRAME 01 / 01
STRUCT. / AKARI THERAPEUTICS
/ Tampa, Florida and London, UK
CAPT. / 02.06.26 11:54:29Z
SIGNAL / 60 / 100
Image relayed by The Biotech Voyager during pass over structure Akari Therapeutics. Resolution as transmitted.
001Vital Statistics
DATA LOCKED
Designation
Akari Therapeutics
Coordinates
Tampa, Florida and London, UK
Stage
Preclinical
Type
Therapeutics
Modalities
ADC · antibody
Therapeutic area
Oncology
002Signature Detected
EVENT DETECTED
Event type
Preclinical combination data, ASCO abstract accepted
Magnitude
Synergy reported in KRAS G12C and G12D pancreatic cancer cell lines, no quantitative metrics disclosed
Lead
AKTX-101 paired with adagrasib
Participating
Akari Therapeutics (Nasdaq: AKTX), CEO Abizer Gaslightwala
003Architecture
PLATFORM PROFILE
Target class
TROP2 antibody-drug conjugate with an RNA splicing-modulator payload
Differentiator
PH1 kills by disrupting RNA splicing rather than through tubulin or DNA-damage chemistry, and the mis-spliced proteins it leaves behind can flag the tumor for the immune system
Lead asset
AKTX-101, a TROP2-targeting ADC carrying the PH1 spliceosome-modulating payload
Pipeline depth
AKTX-101 (TROP2) and AKTX-102 (CEACAM5) on the PH1 platform, plus discovery payloads PH5 and PH6
004Voyager Assessment
MACHINE-GENERATED
An accepted ASCO abstract and an investor webcast make a thin news peg, so read this as a mechanism story, not a data story. The interesting part: Akari's TROP2 splicing-payload ADC made adagrasib work harder in KRAS G12C and G12D pancreatic cell lines, the cancer that humbles almost everything. No response numbers came with it, and this is a sub-dollar stock raising five million at a time. Watch whether the pancreatic combo earns its own program or stays a poster, and whether AKTX-101 reaches its first-in-human start in early 2027.
005Adjacent Structures
FRONTIER MAP
Gilead Trodelvy· Approved TROP2 ADCDatopotamab deruxtecan· AstraZeneca TROP2 ADCAdagrasib (Krazati)· BMS KRAS inhibitorSotorasib (Lumakras)· Amgen KRAS inhibitorRevolution Medicines· Pan-KRAS pancreatic pipelineC4 Therapeutics· Degrader antibody conjugates
— End of transmission —This signal was received and processed by The Biotech Voyager and HOUSTON. Transmissions are auto-generated from public sources and platform telemetry. They are not edited for prose. For human analysis and connection to other signals, watch the Tuesday or Thursday mission broadcast aboard the [SHIP]. Field notes — long-form synthesis from the crew — are archived separately.